Skip to main content

Chlorhexidine Gluconate Solution Market Size Worth USD 219.63 Million in 2032 | Emergen Research

Rising number of surgical procedures in hospitals is a major factor driving chlorohexidine gluconate solution market revenue growth.

Vancouver, Nov. 28, 2023 (GLOBE NEWSWIRE) — The global chlorohexidine gluconate solution market size was USD 181.3 Million in 2022 and is expected to register a revenue CAGR of 1.90% during the forecast period. The surge in surgical procedures, especially in hospitals, serves as a primary driver for market expansion. Chlorhexidine gluconate, renowned for its antiseptic and antibacterial properties, is widely employed for skin cleansing before surgical interventions. Notably, the World Health Organization (WHO) recommends a 2% chlorhexidine isopropanol solution for its efficacy.

Surgical Site Infections (SSI) pose a significant concern, occurring in about 5% of all surgeries, with limb amputation procedures carrying a higher risk. According to WHO, limb amputations exhibit the highest SSI occurrence at 14.3 per 100 operations. The market also benefits from the rising global geriatric population, expected to reach 1.4 billion by 2030, fostering an increase in surgical interventions. However, the market faces challenges from raw material price fluctuations affecting chlorhexidine gluconate solution production.

You Can Download Free Sample PDF Copy of this Report @ https://www.emergenresearch.com/request-sample/2532

Product Type Insights: 2% Chlorhexidine Gluconate Solution Dominates Market Share

Among the product types, the 2% chlorhexidine gluconate solution segment led with the largest revenue share in 2022. Widely utilized as an antiseptic agent, the 2% solution effectively reduces microbial flora on the skin, proving valuable in dentistry and mouthwashes. Studies from the National Library of Medicine endorse the effectiveness of 2% chlorhexidine solutions in controlling dental plaque-induced gingivitis.

Application Insights: Surgical Hand Rub Takes the Lead

In terms of applications, the surgical hand rub segment claimed the largest revenue share in 2022. Proper presurgical handwashing, especially with 4% chlorhexidine gluconate solution, is crucial in reducing the risk of Surgical Site Infections. Market growth is further fueled by the introduction of innovative products, such as Whiteley’s Bactol 90% alcohol surgical hand rub, facilitating faster antiseptic action and enhancing patient care.

The preoperative skin preparation segment is expected to witness the highest revenue CAGR during the forecast period. Chlorhexidine-based solutions, recommended by WHO, offer efficient surgical site infection prevention compared to povidone-iodine. The concentration ranging from 0.5%-4.0%, with a notable preference for 2% chlorhexidine, aligns with Centers for Disease Control and Prevention guidelines.

Click to Purchase this Report at an Exclusively Discounted Rate @ https://www.emergenresearch.com/request-discount/2532

Regional Insights: North America Leads, Asia Pacific Shows Significant Growth Potential

North America dominated the market in 2022, accounting for the largest revenue share. The region’s excellent healthcare facilities and substantial healthcare spending, reaching USD 4.3 trillion in 2021, contribute to market growth. A growing geriatric population in the United States propels healthcare spending, emphasizing the market’s significance.

Asia Pacific is poised to experience the fastest revenue growth, attributed to its aging population and an increased focus on healthcare. By 2050, one in four people in Asia is projected to be above 60 years old. Initiatives like India’s National Health Mission and China’s Healthy China 2030 initiative are pivotal in fostering the healthcare system, propelling the chlorhexidine gluconate solution market.

Europe anticipates steady revenue growth, with a notable rise in surgical procedures. The European Commission reports a significant increase in angioplasty surgeries, reaching 1.1 million in 2021 across 25 European countries.

Scope of Research

Report DetailsOutcome
Market size in 2022USD 181.3 Million
CAGR (2023–2032)1.90 %
Revenue forecast to 2032USD 219.63 Million
Base year of estimation2022
Historical data2019–2021
Forecast period2023–2032
Quantitative unitsRevenue in USD Million and CAGR in % from 2023 to 2032
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments coveredProduct type, application, distribution channel, and region
Regional scopeNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country scopeU.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Benelux, Rest of Europe, China, India, Japan, South Korea, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, Rest of MEA.
Key companies profiledXttrium Laboratories, Afton Pharma, MEDICHEM S.A., 3M, BD, Ecolab, Lupin, Sage Products LLC, Clinicept Healthcare Ltd., Coloplast Corp, Convatec Group PLC, Cardinal Health., GAMA Healthcare Ltd, Medline Industries, Inc.

 

Customization scope10 hours of free customization and expert consultation

Major Companies and Competitive Landscape

The global chlorhexidine gluconate solution market is fragmented, with several key players accounting for the majority of market revenue. Major players are deploying various strategies, entering mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing new products and solutions. Some major players included in the global chlorhexidine gluconate solution market report are:

  • Xttrium Laboratories.
  •  Afton Pharma
  • MEDICHEM S.A.
  •  3M
  • BD
  • Ecolab
  • Lupin
  • Sage Products LLC
  • Clinicept Healthcare Ltd.
  • Coloplast Corp
  • Convatec Group PLC
  •  Cardinal Health.
  • GAMA Healthcare Ltd
  • Medline Industries, Inc.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/2532

Strategic Development

  • On 3 April 2023, 3M Health Care today announced the introduction of its new Food and Drug Administration (FDA)-approved 3M SoluPrep S Sterile Antiseptic Solution chlorhexidine gluconate (2% w/v) and isopropyl alcohol (70% v/v) Patient Preoperative Skin Preparation. The product has been shown to provide fast-acting, broad-spectrum antimicrobial activity (in vitro, clinical significance unknown) and persistence in healthy human volunteers for at least 96 hours post-prep.
  • On 26 September, Cosmos Health company a diversified, vertically integrated global healthcare group engaged in innovative Research and Development (R&D), owner of proprietary nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced the expansion of its C-Sept brand with the launch of the new C-Scrub Wash 4% CHG Biocide.

Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/chlorhexidine-gluconate-solution-market

Segments Covered in Report

For the purpose of this report, Emergen Research has segmented the global chlorhexidine gluconate solution market on the basis of product type, application, distribution channel, and region:

  • Product Type Outlook (Revenue, Volume, USD Million, Kilotonnes; 2019-2032)
    • 2% Chlorhexidine Gluconate Solution
    • 4% Chlorhexidine Gluconate Solution
    • 20% Chlorhexidine Gluconate Solution
  • Application Outlook (Revenue, Volume, USD Million, Kilotonnes; 2019-2032)
    • Preoperative Skin Preparation
    • Surgical Hand Rub
    • Skin Wound and General Skin Cleanser
    • Healthcare Personal Hand Hygiene
  • Distribution Channel Outlook (Revenue, Volume, USD Million, Kilotonnes; 2019-2032)
    • Online
    • Offline
  • Regional Outlook (Revenue, Volume, USD Million, Kilotonnes; 2019-2032)
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • U.K.
      • Italy
      • Spain
      • Benelux
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Rest of APAC
    • Latin America
      • Brazil
      • Rest of LATAM
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • South Africa
      • Turkey
      • Rest of MEA

Curated Reports You Shouldn’t Miss: Dive In Now!

Perlite Market By Form (Crude Expanded), By Application (Horticulture & Agriculture, Construction, Industrial), and By Region Forecast to 2028

Recycled Polyethylene Terephthalate Market, By Type (Flakes, Chips), By Product (Clear, Colored), By Source (Bottles & Containers, Films & Sheets, Others), By Application (Bottles & Containers, Fiber, Strapping, Sheet & Film, Others), and By Region Forecast to 2030

Polyaryletherketone Market, By Product Type (Polyether Ether Ketone, Polyether Ketone), By Filler Type (Unfilled, Carbon Filled), By Application (Oil & Gas, Electrical & Electronics, Automotive, and Aerospace), and By Region Forecast to 2030

Hydraulic Fluid Market, By Distribution Channel (OEMs, Aftermarket), By Base Oil (Mineral Oil, Synthetic Oil, Bio-Based Oil), By End-Use (Construction, Metal & Mining, Agriculture, Oil & Gas, Automotive, Others), and By Region Forecast to 2030

High Performance Plastic Market, By Type (Sulfone Polymers, Polyamides, Fluoropolymers and Others), By End-Use (Aerospace & Defense, Transportation, Electronics, Medical and Others) and By Region Forecast to 2030

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.